Short answer
ZEVRA THERAPEUTICS, INC. (ZVRA) filed an 8-K current report with the SEC on March 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 1.02 (Termination of a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Zevra sells entire SDX portfolio (AZSTARYS/KP415, KP1077) to Commave for $50M total cash: deal closed March 13, 2026.
ZEVRA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Zevra sells entire SDX portfolio (AZSTARYS/KP415, KP1077) to Commave for $50M total cash: deal closed March 13, 2026
- Payment structure: $25M at signing, $20M within ~10 business days, $5M upon delivery of manufacturing/patent records
- Full termination of 2019 AZSTARYS License Agreement and mutual release of all claims: resolves Delaware Chancery Court litigation (C.A. No. 2024-0920)
- Zevra retains underlying SDX patents/know-how but grants Commave a worldwide, royalty-free, perpetual, irrevocable license: no future royalty stream from SDX assets
- Represents a complete exit from the SDX/AZSTARYS franchise; investors should assess what revenue or pipeline value, if any, is lost vs. $50M cash infusion
Item 1.02 · Termination of a Material Definitive Agreement
- Full repayment of $63.0M outstanding principal (including ~$3.0M accrued PIK interest) plus cash interest on March 12, 2026
- Original facility: $100.0M senior secured, $60.0M drawn at inception (April 2024); early repayment ~3 years ahead of April 2029 maturity
- All liens on substantially all company and subsidiary assets now released: balance sheet fully unencumbered
- Lenders HCR Stafford, HCR Potomac, and Perceptive Credit fully exited; eliminates restrictive covenants typically tied to such credit agreements
Item 7.01 · Regulation FD Disclosure
- Zevra Therapeutics issued a press release March 16, 2026 announcing an unspecified "Agreement": full details in Exhibit 99.1
- Nature and financial terms of the Agreement not disclosed in this item; investors should review Exhibit 99.1 for deal specifics
- Reg FD disclosure signals material agreement deemed significant enough to require broad simultaneous public dissemination
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ZEVRA THERAPEUTICS, INC. 8-K filings
Get the next ZVRA 8-K as it lands
Follow ZVRA for push alerts, or ask the research agent what this filing means.